- Home
- Companies
- north america
- immunotherapeutics
Show results for
Refine by
Immunotherapeutics Suppliers In North America
72 companies found
based inPhoenix, ARIZONA (USA)
Creative Medical Technology Holdings, Inc. (CELZ) is a leading commercial stage biotechnology company committed to improving patient lives via a regenerative approach to immunology, urology, neurology, and orthopedics. CELZ is supported by a ...
based inMonmouth Junction, NEW JERSEY (USA)
CytoSorbents Corporation is a leader in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb® is approved in the European Union with distribution in 58 countries around the world, as an extracorporeal ...
based inAlameda, CALIFORNIA (USA)
Since its inception in 1998, AllCells, a Discovery Life Sciences Company, has focused on advancing science in an innovative, collaborative, and client-centric manner. In our corporate video, AllCells’ Founder, Jay Tong, describes his early days in ...
based inNew York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
based inPalo Alto, CALIFORNIA (USA)
Immune-Onc is a clinical-stage company developing a novel class of myeloid checkpoint inhibitors. We believe myeloid checkpoints are the next frontier of immunotherapy for cancer. In collaboration with scientists, our research team is among the ...
Immune-Onc’s lead program is IO-202, an antagonist antibody targeting the myeloid checkpoint LILRB4 (also known as ILT3). Immune-Onc has a Phase I trial underway to evaluate IO-202 as a potential treatment for acute myeloid leukemia (AML) and ...
based inSan Diego, CALIFORNIA (USA)
We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19. Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to ...
Sorrento’s proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors. In-depth analysis of deep sequencing DNA data showed that the G-MAB ...
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based in, NEW JERSEY (USA)
Tevogen Bio is driven by a team of distinguished scientists and experienced biopharmaceutical leaders who have developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from ...
based inSt-Jean, QUEBEC (CANADA)
We are an innovative pharmaceutical company determined to improve the lige of people with allergy. We have developed our biotechnology with you in mind. How could we turn on sharp insights on allergy and precision medicine into a better life for ...
We aim to provide safe, dependable and lasting relief from allergy. We have developed a unique therapeutic approach based on a proprietary allergy vaccine technology to address the specific challenge of allergy (eBioparticle-Potentiated ...
based inNew York, NEW YORK (USA)
Intrommune is a New York City-based biotechnology company dedicated to simplifying allergy immunotherapy. Intrommune’s core technology enables immunotherapeutic agents to be delivered in a specially formulated toothpaste designed to incorporate and ...
Intrommune has developed a novel drug delivery platform—oral mucosal immunotherapy (OMIT)—for the treatment of food allergies. Therapeutic agents are embedding in fully functioning toothpaste so that treatment can be conveniently ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inSacramento, CALIFORNIA (USA)
We are a next-generation biotechnology company creating an AI-powered platform for custom protein design. Our platform develops Novobinders: proprietary protein binders with diagnostic and therapeutic applications. AINovo Biotech works with select ...
based inSan Diego, CALIFORNIA (USA)
Brooklyn ImmunoTherapeutics (BTX) is a clinical-stage biopharmaceutical company committed to creating a world where patients and families with high unmet medical needs have access to effective treatments. We are pioneers in using the latest ...
Cellular reprogramming refers to the process of transforming patient skin cells into pluripotent stem cells, called induced pluripotent stem cells (iPSC). Since 2012 Nobel Prize Winner Dr. Shinya Yamanaka's initial discovery of iPSC in 2006, iPSC ...
based inSan Francisco, CALIFORNIA (USA)
Cypre is a biotechnology company dedicated to overcoming therapeutic resistance for cancer patients. Our 3D Tumor Model Platform engineers the tumor microenvironment in vitro at high throughput for drug efficacy and MOA studies. We are now applying ...
Cypre’s 3D Tumor Models combine the tumor, stromal and immune compartments in a high throughput format to screen targeted drugs and immunotherapy. In 2021, we partnered with Charles River to offer our 3D Tumor Models for drug discovery and ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTallo® is a process developed by Immatics for the manufacture of allogeneic, off-the-shelf, TCR-engineered cellular therapies derived from healthy donors’ gamma delta T ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
Oligonucleotides, composed of 2 to 20 nucleotide units, are increasingly utilized in disease diagnosis and therapeutic applications. They facilitate the introduction of DNA into immune cells, enabling genetic modifications to express chimeric ...
based inBoston, MASSACHUSETTS (USA)
We harness the natural power of the lymph nodes to generate enhanced immune responses against tumors. Our science is defining the future of immunotherapy, with the goal of giving patients who are battling cancer their best possible outcome. We’re ...
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most ...
based inBuffalo Grove, ILLINOIS (USA)
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With ...
based inVirum, DENMARK
Immudex was created in 2009 when it spun off from the diagnostic company Dako, now Agilent. Since then, Immudex has grown in numbers, employees, patents, product lines, partnerships, and customers served. Research, development, and commercial ...
Reliable Identification of SARS-CoV-2-Specific T-Cell Responses. T Cells Take the Lead in COVID-19. A deeper understanding of viral-specific T-cell responses to COVID-19 is needed to explore vaccine responses, long-term immunity, predict patients at ...
